证券代码：603351 证券简称：威尔药业 公告编号：2025-022 南京威尔药业集团股份有限公司关于持股5%以上股东股份质押及解质的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以下简称"公司"）近日获悉公司5%以上股东陈新国、唐群松以及南 京舜泰宗华创业投资合伙企业（有限合伙）（以下简称"舜泰宗华"）所持有的公司股份质押及解质押， 具体情况如下： 南京威尔药业集团股份有限公司董事会 2025 年8 月 19 日 ■ 二、本次股份解除质押情况 1、陈新国 ■ 2、唐群松 ■ 3、舜泰宗华 ■ 三、股东累计质押股份情况 1、截至公告披露日，上述股东唐群松累计质押股份如下： 单位：股 ■ 一、本次股份质押情况 2、截至公告披露日，公司控股股东及其一致行动人累计质押股份如下： 单位：股 ■ 特此公告。 ...

证券代码：603351 证券简称：威尔药业 公告编号：2025-022 南京威尔药业集团股份有限公司 关于持股5%以上股东股份质押及解质的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以下简称"公司"）近日获悉公司 5%以上股东 陈新国、唐群松以及南京舜泰宗华创业投资合伙企业（有限合伙）（以下简称"舜泰宗 华"）所持有的公司股份质押及解质押，具体情况如下： | 股东 名称 | 是否 为控 | 本次质 | 是否 | 是否 | 质押 | 质押 | | 占其所 | 占公司 | 质押融 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股股 东 | 押股数/ 万股 | 为限 售股 | 补充 质押 | 起始日 | 到期日 | 质权人 | 持股份 比例 | 总股本 比例 | 资资金 用途 | | 陈新国 | 是 | 450 | | | 2025-8-15 | 2027-8-13 | 中国银 | 31 ...

（文章来源：每日经济新闻） 威尔药业8月18日晚间发布公告称，公司近日获悉公司5%以上股东陈新国、唐群松以及南京舜泰宗华创 业投资合伙企业（有限合伙）（简称"舜泰宗华"）所持有的公司股份质押及解质押，截至本公告日，吴 仁荣累计质押股数为857万股，占其所持股份比例为46.27%。高正松累计质押股数为846万股，占其所 持股份比例为59.95%。陈新国累计质押股数为450万股，占其所持股份比例为31.89%。舜泰宗华累计质 押股数为370万股，占其所持股份比例为36.48%。 ...

Core Viewpoint - The announcement from 威尔药业 indicates significant share pledges and releases by major shareholders, which may impact the company's stock performance and investor sentiment [1] Share Pledge Summary - Shareholder 陈新国 pledged 4.5 million shares, accounting for 31.89% of his holdings and 3.32% of the company's total share capital [1] - Shareholder 唐群松 pledged 3.85 million shares, representing 27.28% of his holdings and 2.84% of the company's total share capital [1] - Shareholder 舜泰宗华 pledged 3.7 million shares, which is 36.48% of its holdings and 2.73% of the company's total share capital [1] Share Release Summary - 陈新国 released 5.35 million shares from pledge, which is 3.95% of the company's total share capital [1] - 唐群松 released 4.8 million shares from pledge, accounting for 3.54% of the company's total share capital [1]

Group 1 - The stock price of Weier Pharmaceutical reached 31.20 yuan as of the close on August 4, 2025, with an increase of 0.22 yuan from the previous trading day [1] - The stock exhibited a volatility of 2.87% on that day, with significant fluctuations including a rise of over 2% and a drop of over 2% within a 5-minute period during the morning session [1] - The total trading volume for the day was 30,375 hands, with a transaction amount of 93 million yuan [1] Group 2 - Weier Pharmaceutical operates in the chemical pharmaceutical industry, focusing on the research, development, production, and sales of pharmaceutical excipients and synthetic lubricating base oils [1] - The company's products are widely used in pharmaceutical formulations, food, and cosmetics [1] Group 3 - On August 4, the net outflow of main funds for Weier Pharmaceutical was 1.3051 million yuan, but over the past five trading days, there has been an overall net inflow of 3.7662 million yuan [1]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

Core Viewpoint - Weier Pharmaceutical (603351.SH) announced a plan for shareholders to reduce their stakes through centralized bidding, with a focus on the employee stock ownership platform, Shuntai Zonghua [1] Group 1: Shareholder Reduction Plan - Shuntai Zonghua intends to reduce its holdings by up to 1,354,390 shares, representing no more than 1% of the total share capital, between August 20, 2025, and November 17, 2025 [1] - The company's vice president, Zou Jianguo, plans to indirectly reduce his holdings by up to 90,089 shares, while supervisor Li Youhong will reduce his holdings by up to 25,633 shares, both not exceeding 25% of their indirect holdings [1] - The reduction plan does not include shares held by the company's controlling shareholders and actual controllers, Wu Renrong, Gao Zhengsong, and Chen Xinguo, who will not reduce their stakes in any manner [1] Group 2: Pledged Shares - As of the latest disclosure, Wu Renrong, Gao Zhengsong, Chen Xinguo, and Shuntai Zonghua have pledged a total of 26,680,000 shares, accounting for 46.90% of their holdings and 19.70% of the company's total share capital [2] - Wu Renrong holds 18,521,981 shares (13.68%), with 8,570,000 shares pledged, while Gao Zhengsong and Chen Xinguo hold 14,111,986 shares (10.42%) each, with 8,460,000 and 5,350,000 shares pledged respectively [3] Group 3: Company Financials - Weier Pharmaceutical raised a total of 591,667,850.00 yuan from its initial public offering, with a net amount of 538,497,386.71 yuan intended for projects including a 20,000t/a injection drug excipient and general pharmaceutical excipient production base [4] - The total issuance costs amounted to 53,170,463.29 yuan, with underwriting and sponsorship fees of 41,509,433.96 yuan [5]

Policy Developments - The National Medical Products Administration (NMPA) has released a draft for public consultation regarding the adjustment of medical device classifications, aiming to optimize the registration and filing requirements for medical devices [1] Drug Approval - Yuyuan Pharmaceutical's YKYY029 injection has received clinical trial approval for treating hypertension, marking a significant step in the development of a novel siRNA drug [2] - Hengrui Medicine has received clinical trial approvals for four drugs, including SHR-8068 injection and Abediterib injection, with total R&D investments amounting to approximately 20.33 million yuan [3] Financial Reports - Microchip Biotech expects a net profit of 30.06 million yuan for the first half of 2025, driven by increased sales from new drug listings and optimized sales strategies [4] - China National Pharmaceutical Modern reported a 6.46% decline in net profit for the first half of the year, attributed to decreased sales and prices of certain antibiotics and other products [5] Capital Market - Tigermed announced the sale of its stake in Lixin Pharmaceutical for approximately 34.11 million USD, reflecting a strategic move in the context of the domestic pharmaceutical industry's consolidation [6] Industry Events - A breakthrough in brain-computer interface technology has been achieved in Shanghai, allowing patients with speech impairments to communicate through decoded brain activity [8] - Yuan Da Pharmaceutical's innovative nasal spray for dry eye treatment has received approval and its first prescriptions have been issued, providing a new treatment option for patients [9] Debt Resolution - Kangmei Pharmaceutical has reached a settlement agreement to resolve historical debt issues for 43.5 million yuan, facilitating the closure of related legal matters [10] Market Sentiment - Weier Pharmaceutical announced plans for its employee stock ownership platform to reduce its holdings by up to 1% of the company's shares, driven by shareholder funding needs [11]